• Contact us
  • Customer support
  • Login
  • Home
  • Technology
    • Introduction to Ex Vivo Lung Perfusion
    • The Ex Vivo Lung Perfusion Process
    • Clinical
    • Protocols
    • Starting your clinical EVLP program
    • Articles about EVLP
    • EVLP with Manual method
    • EVLP with XPS™
    • Training and workshops
    • Patents
  • Products
    • Our Products
    • XPS™
    • XPS Disposable Lung Kit™
    • STEEN Solution™
    • PERFADEX® Plus
    • XVIVO
      Organ Chamber™
    • XVIVO
      Lung Cannula Set™
    • Instruction for Use
  • Knowledge
    • NOVEL Lung Trial
    • Literature
    • Insights
  • Media
    • Videos
    • Webinars
    • Establishing a successful EVLP program
  • About us
    • About XVIVO
    • History
    • Our market
    • News
    • Career
    • Working at XVIVO
  • Corporate
    • Corporate
    • The share
      • Info
      • Ownership structure
      • Insiders (PDMRs)
    • Press releases
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
    • Financial calendar
    • Financial reports
    • Financial reports – ESEF
    • Prospectus and material offerings
      • Material offerings
      • Prospectus
    • Financial presentations
      • Capital Markets Day
      • Earnings calls
    • Corporate governance
      • Article of Association
      • General meetings
      • Board of Directors
      • Senior Management
      • Auditors
      • Board Committees
      • Board and Senior Management share holdings
      • Guidelines for remuneration
      • Nomination Committee
      • Corporate Governance Reports
    • Analyst Coverage
    • Code of Conduct
    • Environmental Policy
    • Code of Conduct for Suppliers
    • Privacy policy
    • Contact us
    • Subscribe
    • Thank you
    • Error
XVIVO
  • Contact us
  • Customer support
  • Home
  • Technology
    • Introduction to Ex Vivo Lung Perfusion
    • The Ex Vivo Lung Perfusion Process
    • Clinical
    • Protocols
    • Starting your clinical EVLP program
    • Articles about EVLP
    • EVLP with Manual method
    • EVLP with XPS™
    • Training and workshops
    • Patents
  • Products
    • Our Products
    • XPS™
    • XPS Disposable Lung Kit™
    • STEEN Solution™
    • PERFADEX® Plus
    • XVIVO
      Organ Chamber™
    • XVIVO
      Lung Cannula Set™
    • Instruction for Use
  • Knowledge
    • NOVEL Lung Trial
    • Literature
    • Insights
  • Media
    • Videos
    • Webinars
    • Establishing a successful EVLP program
  • About us
    • About XVIVO
    • History
    • Our market
    • News
    • Career
    • Working at XVIVO
  • Corporate
    • Corporate
    • The share
      • Info
      • Ownership structure
      • Insiders (PDMRs)
    • Press releases
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
    • Financial calendar
    • Financial reports
    • Financial reports – ESEF
    • Prospectus and material offerings
      • Material offerings
      • Prospectus
    • Financial presentations
      • Capital Markets Day
      • Earnings calls
    • Corporate governance
      • Article of Association
      • General meetings
      • Board of Directors
      • Senior Management
      • Auditors
      • Board Committees
      • Board and Senior Management share holdings
      • Guidelines for remuneration
      • Nomination Committee
      • Corporate Governance Reports
    • Analyst Coverage
    • Code of Conduct
    • Environmental Policy
    • Code of Conduct for Suppliers
    • Privacy policy
    • Contact us
    • Subscribe
    • Thank you
    • Error
  • Corporate
  • The share
    • Info
    • Ownership structure
    • Insiders (PDMRs)
  • Press releases
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012
  • Financial calendar
  • Financial reports
  • Financial reports – ESEF
  • Prospectus and material offerings
    • Material offerings
    • Prospectus
  • Financial presentations
    • Capital Markets Day
    • Earnings calls
  • Corporate governance
    • Article of Association
    • General meetings
    • Board of Directors
    • Senior Management
    • Auditors
    • Board Committees
    • Board and Senior Management share holdings
    • Guidelines for remuneration
    • Nomination Committee
    • Corporate Governance Reports
  • Analyst Coverage
  • Code of Conduct
  • Environmental Policy
  • Code of Conduct for Suppliers
  • Privacy policy
  • Contact us
  • Subscribe
  • Thank you
  • Error

XVIVO Perfusion Interim report January – June 2016

ACQUISITION OF VIVOLINE STRENGTHENS XVIVO’S PRODUCT AND R&D PORTFOLIO

SECOND QUARTER 2016 (APR – JUN)

• Net sales in the quarter amounted to SEK 34.5 (29.1) million, corresponding to an increase of 18 percent. Net sales of non-Durable goods* in the quarter amounted to SEK 29.8 (27.4) million, corresponding to an increase of 9 percent in SEK and 11 percent in local currency.
• Operating income before depreciation and amortization (EBITDA) excluding one-time expenses increased by 51 percent and amounted to SEK 6.9 (4.6) million, corresponding to an EBITDA margin of 20 percent. One-time expenses of SEK 2.2 million related to the Nasdaq Stockholm main market listing and the public offer for Vivoline have been charged against the quarter. EBITDA amounted to SEK 4.8 (4.6) million, corresponding to an EBITDA margin of 14 percent.
• Net income amounted to SEK 1.5 (1.0) million, resulting in earnings per share of SEK 0.07 (0.05), affected by amortization and depreciation of SEK 3.1 (2.9) million.
• Cash flow from operating activities was SEK 8.1 (8.8) million.
• Total sales from warm perfusion (STEEN Solution™, products and services related to the use of the XPS™ and XPS™) accounted for 42 (39) percent of the total sales.
• 3 XPS™ contracts were signed in the USA during the quarter, whereof 2 were shipped.
• During the quarter XVIVO Perfusion acquired 97 percent of the shares and 99 percent of the 2015/2016 warrants in the listed company Vivoline Medical AB. The combined company creates more resources and competence to take Professor Stig Steen’s world-leading research in the field of heart transplantation to a commercial phase. The acquisition also strengthens XVIVO Perfusion’s market position in the field of lung transplantation.
• The first patient in the clinical study with PrimECC® was included. PrimECC® is a CE marked and patent-protected product, developed to prime the heart-lung machine before open heart surgery.
• STEEN Solution™ was used for the first time to give localized delivery of a chemotherapy agent to a patient suffering from metastatic lung sarcoma through In-Vivo Lung Perfusion (IVLP).
• XVIVO Perfusion’s share warrant program 2016/2018, which was offered to employees, was fully subscribed.

THE PERIOD 2016 (JAN – JUN)

• Net sales in the period amounted to SEK 68.0 (60.9) million, corresponding to an increase of 12 percent. Net sales of non-Durable goods* in the period amounted to SEK 58.8 (52.5) million, corresponding to an increase of 12 percent in SEK and 13 percent in local currency.
• Operating income before depreciation and amortization (EBITDA) excluding one-time expenses increased by 56 percent and amounted to SEK 14.2 (9.1) million, corresponding to an EBITDA margin of 21 percent. One-time expenses of SEK 4.6 million related to the Nasdaq Stockholm main market listing and the public offer for Vivoline have been charged against the period. EBITDA amounted to SEK 9.6 (7.5) million, corresponding to an EBITDA margin of 14 percent.
• Net income amounted to SEK 2.6 (1.0) million, resulting in earnings per share of SEK 0.12 (0.05), affected by amortization and depreciation of SEK 6.2 (5.6) million.
• Cash flow from operating activities was SEK 13.3 (2.9) million. Cash at bank increased by SEK 0.6 million to SEK 41.8 million during the period, even though the Vivoline acquisition affected cash with SEK -7.6 million.
• Total sales from warm perfusion (STEEN Solution™, products and services related to the use of the XPS™ and XPS™) accounted for 41 (42) percent of the total sales.
• During the period 5 XPS™ were sold, of which 2 to Europe and 3 to the US. France and Switzerland were new countries that got access to the XPS™ during the period.
• XVIVO Perfusion AB’s shares were admitted for trading on Nasdaq First North Premier 8 February 2016. The company's shares will continue trading with the same short name and ISIN code.

SIGNIFICANT EVENTS AFTER THE END OF THE QUARTER

• On July 14 the extended acceptance period for the offer for the shares and warrants of series 2015/2016 in Vivoline Medical AB was closed. During the extended acceptance period further 179,097 shares and 28,155 warrants were accepted, whereby XVIVO Perfusion became the owner of 98.6 percent of the shares and 99.6 percent of the warrants. Therefore, the Board decided to issue 30,065 new shares in XVIVO Perfusion as payment for the acquired shares and warrants.
• At the time of publication of this report, 39 clinics have access to the XPS™ and LS-1**, including 20 clinics in the US and 19 clinics in Europe and the rest of the world.

CONFERENCE CALL

CEO Magnus Nilsson will present the report in a conference call at 2 p.m. CET on Friday, July 15, 2016. Telephone: +44 (0) 1452 555566, enter code 41101325.

July 15, 2016
Gothenburg
XVIVO Perfusion AB (publ)
Magnus Nilsson, CEO
 

* Durable goods are sales revenues from the XPS™.
** LS-1 is the Vivoline EVLP machine.

For further information please contact:

Christoffer Rosenblad, CFO, +1 720 616 2101, christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com

For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com

The information was submitted for publication on July15, 2016 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

About us

Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives.
Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine.
XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on three continents. The company is listed on Nasdaq.

Contact

Visiting address:
Swedish Office
XVIVO Perfusion AB
Entreprenörsstråket 10
431 53
Sweden

Phone: +46 31 788 21 50
Fax: +46 31 788 21 69
info@xvivogroup.com

 

Report a violations or breach here: Whistleblower

  • Home
  • Technology
  • Products
  • Knowledge
  • Media
  • About us
  • Corporate

Copyright © 2023 XVIVO. All rights reserved.

Design mkmedia
To top

We use cookies to improve the user experience on XVIVO. Read more about Cookies

Approve